MedTrace Logo

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

NCT05408936 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-05-14

No results posted yet for this study

Summary

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function.

The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit.

A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

SGLT2 inhibitor

Patients receive an SGLT2 inhibitor as part of theirn routine care.

Sponsors & Collaborators

  • University of Patras

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-03
Primary Completion
2023-12-01
Completion
2024-06-01
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05408936 on ClinicalTrials.gov